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Abstract
Background: Escherichia coli (E. coli) is the most common 
cause of urinary tract infection (UTI) and typically treated 
with antibiotics. Unrestricted use of antibiotics may lead to the 
emergence of antibiotic-resistant bacteria. The present study 
aimed to isolate and characterize phages against E. coli from 
infected urine samples and to determine the lytic activity of 
phages against E. coli in vitro.
Methods: The present experimental study was conducted in the 
Laboratory of Bouali Sina Hospital (Sari, Iran) in May 2018. E. 
coli was identified from nine urine samples of patients with UTI 
using conventional microbiological methods. Bacteriophages 
were isolated from the infected urine specimens, and their 
lytic activity was determined using the spot test. The titer of 
the bacteriophages was measured using the double-layer agar 
technique. The morphology of the bacteriophages was revealed 
using transmission electron microscopy, and the latent time 
period and burst size were determined. Data were analyzed 
using the SPSS software package.
Results: E. coli was isolated from nine infected urine samples. 
The lytic activity of bacteriophages against E. coli was determined 
using the spot test by observing the formation of inhibition 
zones. Transmission electron microscopy showed E. coli phages 
belonging to the Myoviridae family. The latent time period was 20 
minutes with a burst size of 1,200 plaque-forming unit (PFU) per 
infected cell. The results of the double-layer agar assay showed 
that the titer of bacteriophages was 20×108 PFU/mL.
Conclusion: The E. coli bacteriophage was isolated from 
infected urine samples and characterized, and their lytic activity 
against E. coli was determined in vitro.
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What’s Known
• Escherichia coli (E. coli) is 
responsible for 75% of the urinary tract 
infections and typically treated with 
antibiotics.
• Unrestricted use of antibiotics has 
led to the emergence of a new class 
of drug resistance enzymes called 
extended-spectrum beta-lactamases 
(ESBL) and ESBL producing strains.
What’s New
• Due to the global rise in antibiotic 
resistance, phages have attracted 
attention as an alternative to antibiotics.
• E. coli bacteriophages were 
isolated from infected urinary specimens, 




Urinary tract infection (UTI) is the most common cause of 
nosocomial infections and the second most common infection in 
humans. Most UTIs are caused by normal colon bacteria such as 
Klebsiella pneumoniae, Escherichia coli (E. coli), Proteus, and 
Pseudomonas aeruginosa. Annually, about 150 million people 
are infected with UTI caused by E.coli.1
Isolation of Escherichia coli bacteriophages from infected urine samples against E. coli
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E. coli strains that cause UTIs (uropathogenic 
E. coli) are responsible for 75% of UTI, including 
40-50% of UTI prevalence in women and 5% in 
men. E. coli is a Gram-negative bacteria of the 
Enterobacteriaceae family causing several human 
infections such as sepsis, gastroenteritis, neonatal 
meningitis, gallbladder and bile duct infections, 
wound infection, pneumonia, peritonitis, and 
especially UTI and kidney failure.2-5
Typically, antibiotics such as aminoglycosides, 
fluoroquinolones, and beta-lactam are used to 
treat E. coli infections. Up to date, unrestricted 
use of antibiotics has led to the emergence of 
a new class of drug resistance enzymes called 
extended-spectrum beta-lactamases (ESBL) and 
ESBL-producing strains. A global rise in antibiotic 
resistance, resulting from the physicians’ 
tendency to prescribe newer drugs, has also 
undermined empirical treatment.6-8 Therefore, 
it is essential to consider alternative medicine 
to prevent and treat UTI instead of resorting to 
antibiotics as the first choice. Recently, phages 
have attracted the attention of physicians as an 
alternative to antibiotics.9-11 Phages, used as 
an individual phage or as a cocktail of several 
phages, have lytic activity without affecting 
normal flora. The main advantage of phage 
therapy over the standard antibiotics therapy 
is that phage cocktail reduces the possibility of 
developing phage-resistant bacteria.12, 13 
In previous studies, phages against E. coli 
were isolated (from sewage, hospital sewage, 
polluted rivers, and human and animal feces) with 
the aim of developing a phage therapy to target 
photogenic species of E. coli.14-16 Another study 
reported the effect of oral application and topical 
treatment of phage cocktail on patients infected 
with UTI.17 Chibeu and colleagues investigated 
and confirmed phage activity against biofilms of 
uropathogenic E. coli.18 A study also confirmed 
the lytic activity of commercial phages against 
E. coli isolated from patients with UTI.19 Some 
other studies have suggested that the pattern 
of antibiotic resistance of E. coli and its specific 
phages vary in different regions.20, 21
The present study aimed to isolate and 
characterize the lytic phages against E. coli 
from the urine samples of patients with UTI. 
In addition, lytic phage activity against E. coli 
with different antibiotic resistance patterns was 
determined in vitro and compared to E. coli 
phages in other regions.  
Materials and Methods
The present experimental study was conducted 
in the Laboratory of Bouali Sina Hospital (Sari, 
Iran) in May 2018.
Isolation of E. coli from Infected Urine Samples
E. coli was isolated from nine urine samples of 
patients with UTI and identified using conventional 
microbiological methods (culture on blood agar, 
MacConkey agar, and eosin-methylene blue 
agar; all from QUELAB, USA). The plates were 
incubated at 37 °C for 24 hours. The pure isolates 
were characterized and identified through Gram-
staining and with biochemical tests such as 
catalase, Simmons citrate agar, indole production, 
methyl-red and Voges-Proskauer (MR-VP), 
and triple sugar iron agar (TSI).22 Sensitivity to 
antibiotics agents was determined using the 
disk diffusion method in accordance with the 
guidelines from the Clinical and Laboratory 
Standards Institute (CLSI). The antibiotic discs 
used were: Nalidixic acid (30 μg), Cefixime (5 μg), 
Piperacillin (100 μg), Amikacin (30 μg), gentamicin 
(10 μg), ceftriaxone (30 μg), Nitrofurantoin (300 
μg), Ampicillin-Sulbactam acid (10/10 μg), and 
ceftazidime (30 μg); all from Rosco, USA.22
Isolation of E. coli Bacteriophage
Initially, the urine samples were stored at 4 °C. 
An equal volume of 2X Luria-Bertani (LB) broth 
(QUELAB, USA) containing E. coli was added 
to each urine sample and incubated overnight 
at 37 °C with shaking. The culture was then 
centrifuged at 10,000 ×g for 10 minutes at 4 °C 
and the supernatant was filtered through Millipore 
filters with 0.22 μm pore size (Millipore, USA).23, 24
Determination of the Host Range using Spot Test
The overnight E. coli cultures (100 μL) from 
the nine samples were individually mixed with 
3 mL top agar and poured into Petri dishes 
containing bottom agar, and subsequently 10 μL 
of isolated phages was added. The dishes were 
incubated at 37 °C overnight. The following day, 
the dishes were checked for inhibition zones.23, 24
The Titer of Bacteriophages 
A double-layer agar assay was performed 
to determine the titer of bacteriophages. The 
E. coli in the LB medium was inoculated and 
shook at 37 °C until the optical density at 
600 nm was reached. The serial dilutions of 
phages were prepared in seven tubes and two 
additional tubes (8 and 9) were used as negative 
and positive controls, respectively. The diluted 
phages (100 µL) were added to 100 µL E. coli 
and top agarose (3 mL) was added onto the 
LB agar plate. The plates were inverted and 
incubated at room temperature overnight, after 
which the plaques were counted.23, 24
Electron Microscope Observation of Phages
Bacteriophages were concentrated by 
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centrifugation at 25,000 ×g for 60 minutes using 
a high-speed centrifuge. The purified phages 
were deposited on carbon-coated copper grids 
(Sigma-Aldrich, Germany) and stained with 2% 
uranyl acetate (pH=4-4.5). After staining, phages 
were observed using a Philips CM 300 electron 
microscope (Philips, USA) at 150 kV.23, 24
The Single-Step Growth Curve
The phage lysate (200 μL) was added to 
200 μL of LB broth (containing bacteria) and 
pre-incubated for 10 minutes at 37 °C to allow 
adsorption of the phages. A row of 16 sterile 
capped tubes were divided into four groups 
and aseptically added 900 μL LB broth to each 
tube. The phages were diluted in the LB broth 
by adding 100 μL to the first tube, mixed, and 
100 μL was transferred to the second tube in the 
series (“1” to “4”). Then, 200 μL of an overnight 
culture of the bacteria was mixed with 200 μL of 
the diluted phages (“1” to “4”). The tubes were 
pre-incubated at 37 °C for 10 minutes to 40 hours 
to allow adsorption of the phages. At intervals, a 
sample was removed from the mixture and the 
number of free phages counted using a plaque 
assay. Petri dishes were incubated overnight at 
37 °C. The following day, the number of plaques 
was counted and PFU/mL was calculated; equal 
to the number of plaques times the dilution factor 
(inverse of the dilutions).23, 24
Results
The results of the conventional microbiological 
method confirmed the isolation of E. coli strains 
from the infected urine samples (table 1). The 
sensitivity to antibiotics agents was determined in 
accordance with the CLSI guidelines. As shown 
in figure 1, the results revealed that four E. coli 
isolates were resistant to Nalidixic acid (30 μg), 
Cefixime (5 μg), Piperacillin (100 μg), ceftriaxone 
(30 μg). These isolates were however sensitive to 
Amikacin (30 μg), Gentamicin (10 μg), Ampicillin-
Sulbactam acid (10/10 μg), and Nitrofurantoin 
(300 μg); but semi-sensitive to ceftazidime (30 
μg). Three other E. coli isolates were resistant to 
Nalidixic acid (30 μg), Cefixime (5 μg), Piperacillin 
(100 μg), ceftriaxone (30 μg), and ceftazidime (30 
μg); but sensitive to Amikacin (30 μg), Gentamicin 
(10 μg), Ampicillin-Sulbactam acid (10/10 μg), 
and Nitrofurantoin (300 μg). The other two E. coli 
isolates were resistant to Nalidixic acid (30 μg), 
Piperacillin (100 μg), and ceftriaxone (30 μg); 
however, sensitive to Amikacin (30 μg), Ampicillin- 
Sulbactam acid (10/10 μg), Nitrofurantoin (300 μg), 
and ceftazidime (30 μg), but semi-sensitive to 
Gentamicin (10 μg) and Cefixime (5 μg).
The host range of isolated phages was 
determined using spot testing and inhibition 
zones were observed in all samples. The 
results indicated that bacteriophages have lytic 
activity against nine E. coli strains with antibiotic 
susceptibility patterns (figure 2). The results of 
the double-layer agar assay showed that the titer 
of bacteriophages was 20×108 PFU/mL. Electron 
microscopy was performed by negative staining 
with 2% uranyl acetate (ACROS, Belgium) 
(pH=4-4.5) at 150 kV. The results showed one 
isolated phage group with an icosahedral head 
(60 nm) and a long non-contractile tail (200 nm). 
The isolated bacteriophages belonged to the 
Myoviridae family (order: Caudovirales); figure 3. 
The results of the single-step growth curve 
showed that the latent time period of isolated E. 
coli bacteriophages was 20 minutes with a burst 
size of 1200 PFU per infected host.
Table 1: The results of conventional microbiological methods identified E. coli strains from infected urine samples
Test Result
Gram staining Gram-negative, rod-shaped bacteria
Growth on MacConkey agar Positive
Growth on Eosin methylene blue agar Positive
TSI test A/A
Citrate test Negative
Methyl-red and Voges-Proskauer tests +/-
Indole test Positive
 TSI: Triple Sugar Iron agar
Figure 1: Disk diffusion method showed antibiotic 
susceptibility of nine isolated Escherichia coli bacteria from 
urinary culture of patients with urinary tract infection.
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Discussion
In the present study, the phage against E. coli 
was isolated from the urine sample of patients 
with UTI and the lytic activity of phages was 
confirmed with the spot test. The images 
obtained from the electron microscope revealed 
the separation of a phage type with a phenotypic 
attribute belonging to the Myoviridae family, with 
an icosahedral head and a 200-nm tail. Phages 
related to T7 have been classified into four groups 
in terms of amino acid of major capsid proteins, 
including Exo-T-even, Schizo-T-even, Pseudo-
T-even, and T-even.25 Our results showed that 
the lytic activity of this phage on different strains 
of E. coli was different in terms of their resistance 
pattern to antibiotics. A previous study showed 
that the lytic phage T4 and T6 had a limited 
hosting range, but phage KEP10 displayed lytic 
activity against a wide range of hosts.25 Phages 
which were separated from different sources 
had different lytic activity. Ghasemian and others 
isolated 32 phages from the rivers in 32 cities in 
Iran. They showed that only the phage isolated 
from the city of Nowshahr had lytic activity 
against E. coli.26 Moreover, they reported that 
even the isolated phages from one region had 
different sources and lytic activities. Another 
study conducted in the northwest of Iran showed 
that the phages isolated from urban sewage had 
a higher impact against E. coli compared with 
those isolated from the rivers.27
In a study by Galtie and others, AL505_
P1, AL505_P2, AL505_P3 phages were 
isolated from sewage which belonged to the 
Podoviridae, Myoviridae, and Siphoviridae 
families, respectively. The lytic activity of these 
phages against the E. coli AL505 strain, caused 
by uropathogenic E. coli isolated from a patient 
with pyelonephritis, was confirmed.28 
In the present study, the latent time period of 
isolated E. coli bacteriophages was 20 minutes, 
and the number of viable progenies per infected 
host was 1200 PFU per infected host. However, 
another study reported a latent time period of 24 
minutes in phages isolated for sewage water, 
which belonged to the Myoviridae family.29 
Moreover, Pouillot and others reported the 
latent time period of Podoviridae against E. coli 
strain as 25 minutes.30 Dufour and others31 used 
bacteriophage LM33-P1 to infect the E. coli 
O25b strain, which is highly resistant to beta-
lactams and fluoroquinolones. They showed a 
latent time period of 9 minutes in vitro against 
this phage strain. Also, its lytic activity in vivo 
against UTI, septicemia, and meningitis caused 
by E. coli was confirmed. Their findings indicated 
the potential of lytic phages for the treatment of 
UTI caused by E. coli. 
The main limitation of the present study, 
due to financial constraints, was that genome 
sequencing of the isolated bacteriophages was 
not performed.
Conclusion
E. coli bacteriophages were isolated from 
infected urinary specimens, and their lytic activity 
against E. coli was characterized by different 
antibiotic resistance patterns in vitro. These 
bacteriophages differed in terms of features 
and lytic activity depending on the source of the 
phage. 
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